Data / Drug companies / Pyrophosphate Analog DNA Polymerase Inhibitor
Pyrophosphate Analog DNA Polymerase Inhibitor drugs: 1 drug from 10 companies in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Pyrophosphate Analog DNA Polymerase Inhibitor is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 11 products in this class from 10 companies, covering 1 drug by generic name. The main marketing category is generic drugs (ANDA), and the newest product started marketing on September 25, 2026.
The request: Get every company that lists a Pyrophosphate Analog DNA Polymerase Inhibitor drug in the FDA NDC directory, with headquarters, website and size. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 10Companies
- 11Products
- 1Drugs by generic name
Drugs in the Pyrophosphate Analog DNA Polymerase Inhibitor class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Foscarnet sodium | 11 | 10 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Clinigen Limited | 2 | injection, solution | New drug applications (NDA) | April 1, 2014 |
| Amneal Pharmaceuticals LLC | 1 | injection | Generic drugs (ANDA) | March 4, 2024 |
| Baxter Healthcare Corporation | 1 | injection, solution | Generic drugs (ANDA) | August 28, 2023 |
| Caplin Steriles Limited | 1 | injection, solution | Generic drugs (ANDA) | May 20, 2026 |
| Fresenius Kabi USA, LLC | 1 | injection, solution | Generic drugs (ANDA) | January 29, 2021 |
| Gland Pharma Limited | 1 | injection, solution | Generic drugs (ANDA) | April 21, 2021 |
| Heritage Pharmaceuticals Inc. D/B/A Avet Pharmaceuticals Inc. | 1 | injection, solution | Generic drugs (ANDA) | June 5, 2023 |
| Hikma Pharmaceuticals USA Inc. | 1 | injection, solution | Generic drugs (ANDA) | November 29, 2023 |
| Sagent Pharmaceuticals | 1 | injection, solution | Generic drugs (ANDA) | May 15, 2021 |
| Somerset Therapeutics, LLC | 1 | injection, solution | Generic drugs (ANDA) | September 25, 2026 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 10 | 90.9% |
| Injection | 1 | 9.1% |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.